Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2001

View Archived Issues

Xenerex and Peregrine establish collaboration for solid tumor antibody therapies

Samaritan and Georgetown enter research collaboration

Molecules with antiangiogenic activity discovered by AEterna

Deoxyspergualin analogue is effective in animal models of graft rejection and lupus

Antizol for methanol poisoning granted orphan drug status in E.C., priority review in Canada

FDA grants CytRx's Flocor fast track status

Celera Genomics to acquire AxyS

Diovan sNDA for heart failure receives priority review by FDA

rhEndostatin successfully completes phase I clinical evaluation

RegeneRx focuses on thymosin beta 4 for chronic wound treatment

Phase I/II clinical testing begins of VLTS-589 for peripheral arterial disease

New low-dose triphasic oral contraceptive from Organon now available in U.S.

CIPF obtains rights to antigen delivery technology for anticancer, antiinfectious applications

Lilly compound reduces fracture risk, increases bone strength in postmenopausal osteoporosis

Advanced Magnetics seeks FDA approval to begin clinical evaluation of iron replacement therapy

Bayer presents pipeline overview at Goldman Sachs Healthcare Conference

Two Novuspharma compounds advance to phase II for gastric cancer

HemispheRx Biopharma commences new clinical studies of Ampligen in multidrug-resistant HIV

Atacand/Zestril combination trial begins

FDA extends BLA action date for Lilly's drotrecogin alfa, new brand name accepted

Mutant HLA class I molecules as novel approach to xenotransplantation and bone marrow transplant

3-DP receives NIH funding

Protein for breast cancer diagnostic/prognostic and staging information available for licensing

6-MNA prodrugs with nabumetone-like antiinflammatory activity

p38 MAP kinase inhibitors and their use described by Novartis team

New Na+/H+ exchange inhibitors particularly useful in cardiac ischemia

Tanabe Seiyaku presents small-molecule cell adhesion inhibitors

Antibacterial and antiprotozoal hygromycin-related compounds in development at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...